Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple sclerosis (MS) portfolio of approved and investigational treatments will be presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN) taking place April 10 to 17, in Toronto, Canada. The data presented will focus on Rebif® (interferon beta-1a), an established therapy for relapsing forms of MS, and Cladribine Tablets, a potential oral therapy for relapsing forms of MS currently under regulatory review in a number of countries.

“We have made a commitment as a leading company in this field to advance the treatment of multiple sclerosis and the underlying science”

"We have made a commitment as a leading company in this field to advance the treatment of multiple sclerosis and the underlying science," said Bernhard Kirschbaum, PhD, Executive Vice President, Global Research and Development at Merck Serono, a division of Merck KGaA, Darmstadt, Germany. "The data presented at the upcoming AAN meeting will further contribute to the existing body of knowledge about Rebif® and Cladribine Tablets, as well as to a greater understanding of the disease."

The following abstracts have been accepted for presentation at the 62nd AAN Annual Meeting:

Rebif® (interferon beta-1a)

Platform presentations

- Measures of Early Clinical Activity as Prognostic Factors for Long-Term Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis (presentation S01.005 - Tuesday, April 13, 2010, 2:45 pm ET)

- Subcutaneous Interferon beta-1a Treatment and Pregnancy Outcomes in Patients with Multiple Sclerosis (presentation S40.005 - Wednesday, April 14, 2010, 5:15 pm ET)

Poster presentations

- Assessing the Risk of Malignancy in Patients with Multiple Sclerosis Receiving Subcutaneous Interferon beta-1a (poster P01.167, Tuesday, April 13, 2010, 7:30 am-12:00 pm ET)

- Impact of Medication Adherence to Disease-Modifying Drugs on Severe Relapse, and Direct and Indirect Costs among Employees with Multiple Sclerosis (poster P01.204, Tuesday, April 13, 2010, 7:30 am-12:00 pm ET)

- Interferon Beta-1a Modulation of B Cells: Implications for Relapsing Multiple Sclerosis (poster P04.197, Wednesday, April 14, 2010, 3:00 pm-7:30 pm ET)

Cladribine Tablets

Platform presentation

- Analysis of Clinical and Radiological Disease Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets, in the Double-Blind, 96-Week CLARITY Study (presentation S21.008, Wednesday, April 14, 2010, 3:45 pm ET)

Poster presentations

- Health Resource Utilization in the CLARITY Study (poster P01.205, Tuesday, April 13, 2010, 7:30 am-12:00 pm ET)

- Consistent Efficacy of Cladribine Tablets across Multiple Sclerosis and Patient Characteristics, in the Double-Blind, 96-Week CLARITY Study (poster P02.186, Tuesday, April 13, 2010, 3:00 pm-7:30 pm ET)

- Effects of Cladribine Tablets on Circulating Lymphocyte Subsets in the 96-Week CLARITY Study in Relapsing-Remitting Multiple Sclerosis (RRMS) (poster P04.219, Wednesday, April 14, 2010, 3:00 pm-7:30 pm ET)

SOURCE EMD Serono, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection